Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 END USER MARKET COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE
4.4 SUPPLY CHAIN ECOSYSTEM
4.4.1 PROMINENT COMPANIES
4.4.2 SMALL & MEDIUM SIZE COMPANIES
4.4.3 END USERS
4.5 INDUSTRY INSIGHTS
4.5.1 MICRO AND MACRO ECONOMIC FACTORS
4.5.2 KEY PRICING STRATEGIES
4.6 MARKETED DRUG ANALYSIS
4.6.1 DRUG
4.6.1.1 BRAND NAME
4.6.1.2 GENERIC NAME
4.6.2 THERAPEUTIC INDICATION
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG
4.6.4 DRUG PRIMARY INDICATION
4.6.5 MARKET STATUS
4.6.6 MEDICATION TYPE
4.6.7 DRUG DOSAGE FORM
4.6.8 DOSAGES AVAILABILITY
4.6.9 PACKAGING TYPE
4.6.10 DRUG ROUTE OF ADMINISTRATION
4.6.11 DOSING FREQUENCY
4.6.12 DRUG INSIGHT
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES
4.6.13.1 FORECAST MARKET OUTLOOK
4.6.13.2 CROSS COMPETITION
4.6.13.3 THERAPEUTIC PORTFOLIO
4.6.13.4 CURRENT DEVELOPMENT SCENARIO
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS
4.7.1 OVERVIEW
4.7.2 TARIFF STRUCTURES
4.7.2.1 NORTH AMERICA VS. REGIONAL TARIFF STRUCTURES
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
4.9 EPIDEMIOLOGY OVERVIEW
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER
4.9.2 TREATMENT RATE
4.9.3 MORTALITY RATE
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.9.5 PATIENT TREATMENT SUCCESS RATES
5 REGULATORY FRAMEWORK
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.1.2 REGULATORY APPROVAL PATHWAYS
5.1.3 LICENSING AND REGISTRATION
5.1.4 POST-MARKETING SURVEILLANCE
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND
6.2 RESTRAINTS
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE
6.3 OPPORTUNITIES
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY
7 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE
7.1 OVERVIEW
7.2 BETA EMITTERS
7.2.1 LUTETIUM-177
7.2.2 TERBIUM-161
7.3 ALPHA EMITTERS
7.3.1 ACTINIUM-225
7.3.2 LEAD -212
8 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES
8.1 OVERVIEW
8.2 REACTOR-PRODUCED ISOTOPES
8.3 GENERATOR-PRODUCED ISOTOPES
8.4 OTHERS
9 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 PROSTATE CANCER
9.2.2 NEUROENDOCRINE TUMORS
9.2.3 LIVER CANCER
9.2.4 BRAIN TUMORS
9.2.5 BREAST CANCER
9.2.6 LEUKEMIA
9.3 OTHERS
10 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE
10.1 OVERVIEW
10.2 SMALL MOLECULE LIGANDS
10.3 PEPTIDES
10.4 MONOCLONAL ANTIBODIES
10.5 OTHERS
11 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 ONCOLOGY CENTERS
11.2.2 NUCLEAR MEDICINE DEPARTMENTS
11.3 RADIOPHARMACIES
11.4 RESEARCH INSTITUTES
12 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 NOVARTIS AG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ECKERT & ZIEGLER
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 SHINE TECHNOLOGIES, LLC
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 ACTINIUM PHARMACEUTICALS, INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 PIPELINE PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ALPHA TAU MEDICAL LTD.
15.6.1 COMPANY SNAPSHOT
15.6.2 PIPELINE PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 ARICEUM THERAPEUTICS
15.7.1 COMPANY SNAPSHOT
15.7.2 PIPELINE PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 BAYER AG
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PIPELINE PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 CURIUM
15.9.1 COMPANY SNAPSHOT
15.9.2 PIPELINE PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 IONETIX CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 PIPELINE PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 ISOTOPIA
15.11.1 COMPANY SNAPSHOT
15.11.2 PIPELINE PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 LANTHEUS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LILLY
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PIPELINE PRODUCT PORTFOLIO
15.14 NIOWAVE
15.14.1 COMPANY SNAPSHOT
15.14.2 PIPELINE PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 NMR
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 ONCOINVENT
15.16.1 COMPANY SNAPSHOT
15.16.2 PIPELINE PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 ORANO GROUP
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PIPELINE PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 RADIOPHARM THERANOSTICS LIMITED
15.18.1 COMPANY SNAPSHOT
15.18.2 PIPELINE PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 TELIX PHARMACEUTICALS LIMITED
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PIPELINE PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 TERTHERA
15.20.1 COMPANY SNAPSHOT
15.20.2 PIPELINE PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA CLINICAL TRIAL MARKET FOR NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 5 PENETRATION AND GROWTH PROSPECT MAPPING
TABLE 6 INCIDENCE OF CANCER BY GENDER
TABLE 7 CANCER MORTALITY RATE
TABLE 8 CANCER TREATMENT SUCCESS RATE
TABLE 9 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA REACTOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA GENERATOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA SMALL MOLECULE LIGANDS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA PEPTIDES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA MONOCLONAL ANTIBODIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA RADIOPHARMACIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA RESEARCH INSTITUTES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 43 U.S. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 U.S. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 46 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 47 U.S. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 50 U.S. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 52 CANADA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 CANADA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 55 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 56 CANADA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 59 CANADA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 61 MEXICO BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 MEXICO ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 64 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 65 MEXICO ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 68 MEXICO HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: MULTIVARIATE MODELLING
FIGURE 7 CURVE LINE CHART, BY ISOTOPE
FIGURE 8 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: END USER MARKET COVERAGE GRID
FIGURE 12 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 13 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 TWO SEGMENTS COMPRISE THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 2024
FIGURE 16 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES IS EXPECTED TO DRIVE THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 17 BETA EMITTERS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN 2025 & 2032
FIGURE 18 INCIDENCE BY CANCER SITE
FIGURE 19 CANCER MORTALITY RATE WITH CANCER SITE
FIGURE 20 DROC ANALYSIS
FIGURE 21 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2024
FIGURE 22 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 23 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, CAGR (2025-2032)
FIGURE 24 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2024
FIGURE 26 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2025 TO 2032 (USD THOUSAND)
FIGURE 27 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, CAGR (2025-2032)
FIGURE 28 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, LIFELINE CURVE
FIGURE 29 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2024
FIGURE 30 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 31 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, CAGR (2025-2032)
FIGURE 32 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 33 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2024
FIGURE 34 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 35 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, CAGR (2025-2032)
FIGURE 36 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 37 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2024
FIGURE 38 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 39 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2025-2032)
FIGURE 40 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2024)
FIGURE 42 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)
